Dr. Marc Cluzel

Year of birth 1955

Nationality French

Place of residence Montpellier, France

Initial appointment 2012



Professional development

| Currently | Member of the Supervisory Board of MorphoSys AG as well as member of comparable foreign supervisory board of a commercial enterprise (see below) |
|-------------|--|
| 2011 – 2012 | Executive Vice President of Product Development, HÙYÀ Bioscience International, LLC, San Diego, CA, USA |
| 2009 – 2010 | Executive Vice President of Research & Development, Sanofi-Aventis S.A., Paris, France |
| 2007 – 2009 | Senior Vice President of Science and Medical Affairs, Sanofi-Aventis S.A., Paris, France |
| 2002 – 2011 | Chairman and CEO, Sanofi-Aventis R&D France, Paris, France |
| 1996 – 2001 | Head of Project Direction, Sanofi R&D France, Paris, France |
| 1993 – 1996 | Project Director, Sanofi R&D France, Paris, France |
| 1991 – 1993 | Clinical Pharmacologist, Sanofi R&D France, Montpellier, France |

Education

| 1983 – 1990 | Ph.D. Biochemistry at University of Montpellier, France |
|-------------|--|
| 1973 – 1985 | M.D., Study of Medicine at University of Montpellier, France |

Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises

Moleac Pte. Ltd., Singapore* Member of the Board of Directors

Griffon Pharmaceuticals Inc., Montreal, Canada* Member of the Board of Directors

As of March 2021

^{*}not publicly listed company; group mandate